Investor MPM Oncology Impact Management LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by MPM Oncology Impact Management LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-08-12 13G/A CMPX / Compass Therapeutics, Inc. 8,567,896 5,622,505
2025-02-14 13G CMPX / Compass Therapeutics, Inc. 8,567,896
2025-01-08 13G CNTX / Context Therapeutics Inc. 14,705,882
2023-08-01 13D/A REUN / Reunion Neuroscience Inc 5,129,673 0
2023-06-12 13D REUN / Reunion Neuroscience Inc 5,129,673